Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 68Prostatic Neoplasms 44Leukemia, Myeloid, Acute 35Melanoma 34Lung Neoplasms 28Carcinoma, Non-Small-Cell Lung 28Pancreatic Neoplasms 26Myelodysplastic Syndromes 23Multiple Myeloma 23Colorectal Neoplasms 23Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasms 21Squamous Cell Carcinoma of Head and Neck 19Neoplasm Metastasis 19Lymphoma, Large B-Cell, Diffuse 19Rectal Neoplasms 16Lymphoma, Mantle-Cell 14Carcinoma, Renal Cell 14Triple Negative Breast Neoplasms 13Stomach Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Colonic Neoplasms 13Lymphoma, Follicular 12Uterine Cervical Neoplasms 11Ovarian Neoplasms 11Leukemia, Myelomonocytic, Chronic 11Head and Neck Neoplasms 11Esophageal Neoplasms 11Myeloproliferative Disorders 10Mouth Neoplasms 9

Interventions

pembrolizumab 4Nivolumab 3toripalimab 2sintilimab 2Neoadjuvant Therapy 2Celecoxib 2tislelizumab 1spartalizumab 1relatlimab 1regorafenib 1fludarabine phosphate 1fludarabine 1durvalumab 1denileukin diftitox 1danvatirsen 1camrelizumab 1avelumab 1atezolizumab 1XELOX 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Ipilimumab 1Induction Chemotherapy 1Immunotherapy 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Turcot syndrome × Biopsy × Clear all
NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡